IgG subclasses pattern and high-avidity antibody to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in an unstable hypoendemic region in Iran

Acta Tropica

Volumn 112, Issue 1, 2009, Pages 1-7

  Mehrizi, Akram Abouie ^a,b   Zakeri, Sedigheh ^a   Salmanian, Ali Hatef ^b   Sanati, Mohammad Hossein ^b   Djadid, Navid Dinparast ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

Author keywords

Antibody; Avidity; C terminal region of MSP 1; Immune response; Malaria; Plasmodium vivax

Indexed keywords

CHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN SUBCLASS; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PROTEIN ANTIBODY;

ANTIBODY; ANTIGEN; ENDEMISM; IMMUNE RESPONSE; MALARIA; PARASITE; PROTEIN; VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHILD; CONTROLLED STUDY; DRUG RESPONSE; ENDEMIC DISEASE; FEMALE; HUMAN; INFANT; IRAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; VACCINE PRODUCTION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; IRAN; MALARIA, VIVAX; MALE; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PLASMODIUM VIVAX; YOUNG ADULT;

ASIA; EURASIA; IRAN; MIDDLE EAST;

PLASMODIUM VIVAX;

EID: 68249088730     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2009.05.016     Document Type: Article

References (42)

1. Barat L.M., and Bloland P.B. Drug resistance among malaria and other parasites. Infect. Dis. Clin. North. Am. 11 (1997) 969-987
2. Blackman M.J., Scott-Finntgan T.J., Shai S., and Holder A.A. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. 180 (1994) 389-393
3. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., Hashiro C.Q., Nikaido C.M., Gibson H.L., Lee-Ng C.T., Barr P.J., Yokota B.T., and Hut G.S. A recombinant baculovirus 42-kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 64 (1996) 253-261
4. Chappel J.A., and Holder A.A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60 (1993) 303-311
5. 19 expressed in distinct bacteria vectors. Vaccine 20 (2001) 385-396
6. Del Portillo H.A., Longacre S., Khouri E., and David P.H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4030-4034
7. Egan A.F., Blackman M.J., and Kaslow D.C. Vaccine efficacy of recombinant Plasmodium falciparum Merozoite Surface Protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect. Immun. 68 (2000) 1418-1427
8. Fraser T., Michon P., Barnwell J.W., Noe A.R., Al-Yaman F., Kaslow D.C., and Adams J.H. Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect. Immun. 65 (1997) 2772-2777
9. Freeman R.R., and Holder A.A. Surface antigens of malaria merozoites. A high molecular weight precursor is processed to an 83,000 mol wt form expressed on the surface of Plasmodium falciparum merozoite. J. Exp. Med. 158 (1983) 1647-1653
10. Ferreira M.U., Kimura E.A., De Souza J.M., and Katzin A.M. The isotype composition and avidity of naturally acquired anti-Plasmodium falciparum antibodies: differential patterns in clinically immune Africans and Amazonian patients. Am. J. Trop. Med. Hyg. 55 (1996) 315-323
11. Ferreira M.U., Ribeiro W.L., Tonon A.P., Kawamoto F., and Rich S.M. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 304 (2003) 65-75
12. Galinski M.R., and Branwell J.W. Plasmodium vivax: merozoite invasion of reticulocytes and considerations for malaria vaccine development. Parasitol. Today 12 (1996) 20-29
13. Han H.J., Park S.G., Kim S.H., Hwang S.Y., Han J., Traicoff J., Kho W.G., and Chung J.Y. Epidermal growth factor-like motifs 1 and 2 of Plasmodium vivax merozoite surface protein 1 are clinical domains in erythrocyte invasion. Biochem. Biophys. Res. Commun. 320 (2004) 563-570
14. Hedman K., Lappalainen M., Seppaia I., and Makela O. Recent primary Toxoplasma infection indicated by a low avidity of specific IgG. J. Infect. Dis. 159 (1989) 736-740
15. Holder A.A., Blackman M.J., Burghaus P.A., Chappel J.A., Ling I.T., McCallum-Deighton N., and Shai S. A malaria merozoite surface protein (MSP-1)-structure, processing and function. Mem. Inst. Oswaldo. Cruz. 87 (1992) 37-42
16. Leclerc M.C., Menegon M., Cligny A., Noyer J.L., Mammadov S., Aliyev N., Gasimov E., Majori G., and Severini C. Genetic diversity of Plasmodium vivax isolates from Azerbaijan. Malar. J. 3 (2004) 40
17. Lim C.S., Kim S.H., Kwon S.I., Song J.W., Song K.J., and Lee K.N. Analysis of Plasmodium vivax merozoite surface protein-1 gene sequences from resurgent Korean isolates. Am. J. Trop. Med. Hyg. 62 (2000) 261-265
18. Lim K.J., Park J.W., Yeom J.S., Lee Y.H., Yoo S.B., Oh J.H., Sohn M.J., Bahk Y.Y., and Kim Y.S. Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax. Parasitol. Res. 92 (2004) 384-389
19. Mendis K., Sina B.J., Marchesini P., and Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64 (2001) 97-106
20. Morais C.G., Soares I.S., Carvallo L.H., Fontes C.J., Krettli A.U., and Braga E.M. IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil. Parasitol. Res. 95 (2005) 420-426
21. Nogueira P.A., Alves F.P., Fernandez-Becerra C., Pein O., Santos N.R., Pereira da Silva L.H., Camargo E.P., and Del Portillo H.A. A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect. Immun. 74 (2006) 2726-2733
22. Nomura T., Carlton J.M., Baird J.K., Del Portillo H.A., Fryauff D.J., Rathore D., Fidock D.A., Su X., Collins W.E., McCutchan T.F., Wootton J.C., and Wellems T.E. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J. Infect. Dis. 183 (2001) 1653-1661
23. Park J.W., Moon S.H., Yeom J.S., Lim K.J., Sohn M.J., Jung W.C., Cho Y.J., Jeon K.W., Ju W., Ki C.S., Oh M.D., and Choe K. Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea. Clin. Diagn. Lab. Immunol. 8 (2001) 14-20
24. Pitabut N., Panichakorn J., Mahakunkijcharoen Y., Hirunpetcharat C., Looareesuwan S., and Khusmith S. IgG antibody profile to c-terminal region of Plasmodium vivax merozoite surface protein-1 in Thai individuals exposed to malaria. Southeast Asian J. Trop. Med. Public. Health 38 (2007) 1-7
25. Putaporntip C., Jongwutiwes S., Sakihama N., Ferreira M.U., Kho W.G., Kaneko A., Kanbara H., Hattori T., and Tanabe K. Mosaic organization and heterogeneity in frequency of allelic re-combination of the Plasmodium vivax merozoite surface protein-1 locus. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 16348-16353
26. Rodriguez L.E., Urquiza M., Ocampo M., Curtidor H., Suárez J., Garcia J., Vera R., Puentes A., López R., Pinto M., Rivera Z., and Patarroyo M.E. Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine 20 (2002) 1331-1339
27. Roost H.P., Bachmann M.F., Haag A., Kalinke U., Pliska V., Hengartner H., and Zinkernagel R.M. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1257-1261
28. Sachdeva S., Ahmad G., Malhotra P., Mukherjee P., and Chauhan V.S. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kilodalton fragments expressed in Escherichia coli. Infect. Immun. 72 (2004) 5775-5782
29. Severini C., Menegon M., Di Luca M., Abdullaev I., Majori G., Razakov S.A., and Gradoni L. Risk of Plasmodium vivax malaria reintroduction in Uzbekistan: genetic characterization of parasites and status of potential malaria vectors in the Surkhandarya region. Trans. R. Soc. Trop. Med. Hyg. 98 (2004) 585-592
30. Snounou G., Viriyakosol S., Zhu X.P., Jarra W., Pinheiro L., do Rosario V.E., Thaithong S., and Brown K.N. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol. Biochem. Parasitol. 61 (1993) 315-320
31. Soares I.S., Levitus G., Souza J.M., Del Portillo H.A., and Rodrigues M.M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect. Immun. 65 (1997) 1606-1614
32. Soares I.S., da Cunha M.G., Silva M.N., Souza J.M., Dell Portillo H.A., and Rodrigues M.M. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am. J. Trop. Med. Hyg. 60 (1999) 357-363
33. Suárez-mutis M.C., Cuervo P., Leoratti F.M., Moraes-Avila S.L., Ferreira A.W., Fernandes O., and Coura J.R. Cross sectional study reveals a high percentage of asymptomatic Plasmodium vivax infection in the Amazon Rio Negro area. Brazil Rev. Inst. Med. Trop. Sao. Paulo. 49 (2007) 159-164
34. Tian J.H., Kumar S., Kaslow D.C., and Miller L.H. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect. Immun. 65 (1997) 3032-3036
35. Tanabe K., Mackay M., Goman M., and Scaife J.G. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 195 (1987) 273-287
36. Uthaipibull C., Aufiero B., Syed S.E., Hansen B., Guevara Patino J.A., Angov E., Ling I.T., Fegeding K., Morgan W.D., Ockenhouse C., Birdsall B., Feeney J., Lyon J.A., and Holder A.A. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307 (2001) 1381-1394
37. Wickramarachchi T., Illeperuma R.J., Perera L., Bandara S., Holm I., Longacre S., Handunnetti S.M., and Udagama-Randeniya P.V. Comparison of naturally acquired antibody responses against the C-terminal processing products of Plasmodium vivax Merozoite Surface Protein-1 under low transmission and unstable malaria conditions in Sri Lanka. Int. J. Parasitol. 37 (2007) 199-208
38. Yang C., Collins W.E., Sullivan J.S., Kasalow D.C., Xiao L., and Lal A.A. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect. Immun. 67 (1999) 342-349
39. Zakeri S., Najafabadi S.T., Zare A., and Djadid N.D. Detection of malaria parasites by nested PCR in south-eastern, Iran: Evidence of highly mixed infections in Chahbahar district. Malar. J. 1 (2002) 2
40. Zakeri S., Mamaghani S., Mehrizi A.A., Shahsavari Z., Raeisi A., Arshi S., and Dinparast-Djadid N. Molecular evidence of mixed P. vivax and P. falciparum infections in northern Islamic Republic of Iran. East. Mediterr. Health. J. 10 (2004) 336-342
41. Zakeri S., Mehrizi A.A., Mamaghani S., Noorizadeh S., Snounou G., and Djadid N.D. Population structure analysis of Iranian Plasmodium vivax in areas with different malaria endemicity. Am. J. Trop. Med. Hyg. 74 (2006) 394-400
42. Zeyrek F.Y., Babaoglu A., Demirel S., Erdogan D.D., Ak M., Korkmaz M., and Coban M.C. Short report: analysis of naturally acquired antibody responses to the 19-kd C-terminal region of merozoite surface protein-1 of Plasmodium vivax from individuals in Sanliurfa. Turkey. Am. J. Trop. Med. Hyg. 78 (2008) 729-732